Alarming Spread of Highly Mutated 'Cicada' Variant Sparks Vaccine Concerns in 25 U.S. States

The highly mutated 'Cicada' variant of COVID-19, first identified in South Africa late in 2024, has quietly begun its spread across the United States. Now detected in at least 25 states, this strain has raised alarms among public health officials due to its unprecedented number of mutations—approximately 75 on its spike protein, the part of the virus that vaccines target. These changes make it appear nearly foreign to the immune system, potentially undermining the protection offered by current vaccines and prior infections. While overall U.S. case numbers remain low, the variant's presence is growing steadily.

Symptoms associated with Cicada mirror those of earlier strains but may include additional features like the so-called 'razorblade throat,' a term describing an intensely painful sore throat that some recent variants have been linked to. The CDC lists common signs as runny or stuffy nose, fever, headache, fatigue, sneezing, sore throat, cough, muscle aches, vomiting, diarrhea, and changes in smell or taste. These symptoms are not unique to Cicada but could signal its emergence if they appear in clusters or with unusual severity.

Experts caution that while no definitive evidence yet suggests Cicada is more virulent than previous variants, its novelty poses a challenge. The immune system's lack of prior exposure means it may struggle to mount an effective response, potentially leading to more severe illness in vulnerable populations. The World Health Organization designated BA.3.2—the scientific name for Cicada—as a 'variant under monitoring' in December 2025, signaling the need for closer scrutiny.

The variant's name, 'Cicada,' comes from Dr. T Ryan Gregory, an evolutionary biology professor at the University of Guelph in Canada. Known for coining names like 'Stratus' and 'Pirola' for other variants, Gregory chose the term to reflect the cicada's life cycle—long periods of dormancy followed by a sudden resurgence. This pattern mirrors BA.3.2's trajectory: initially overshadowed by other strains, it resurged in the U.S. after a year-long dormancy.

Despite its mutations, Cicada is not currently the dominant strain in the U.S., where an omicron sublineage called XFG holds that position. However, it accounts for about 30% of cases in Denmark, Germany, and the Netherlands, highlighting its global reach. In the U.S., wastewater surveillance first detected BA.3.2 in Rhode Island in November 2025, months before clinical cases were reported. The first confirmed infections in the U.S. occurred in early January 2026, involving two older adults with preexisting conditions and a young child—all of whom recovered.

The CDC's surveillance network plays a critical role in tracking Cicada. Using lab testing, airport screenings, and wastewater monitoring across 1,450 sewer sites nationwide, officials identified the variant's arrival in the U.S. in June 2025, long before it reached hospitals. Scientists analyze genetic sequences to compare the variant's mutations with current vaccines, assessing how well existing protections might hold up.

Laboratory studies suggest that BA.3.2 may have a reduced ability to attach to human cells compared to other variants, which could explain its slower spread. However, this does not rule out the possibility of future mutations increasing its transmissibility. Public health officials are closely watching for signs of a potential spring surge, as immune systems may be unprepared for a new wave of infections.

The variant's journey from South Africa to the U.S. began with a traveler testing positive at San Francisco International Airport in June 2025. By February 2026, it had been detected in over 130 wastewater samples across two dozen states, as well as in a small number of clinical cases and international travelers. Limited surveillance in many countries may underrepresent its true geographic spread, according to the CDC.

As Cicada continues to circulate, the focus remains on monitoring its behavior and assessing the effectiveness of current vaccines. While no immediate changes to public health measures are planned, experts emphasize the importance of continued vigilance, vaccination, and reporting of unusual symptoms. The variant's story is a reminder that the virus remains an evolving challenge, demanding adaptability in both science and public health strategy.

The Centers for Disease Control and Prevention (CDC) employs advanced bioinformatics tools to analyze genetic sequences from coronavirus samples collected globally. These software systems align viral genomes, identifying mutations and constructing phylogenetic trees that reveal evolutionary relationships between strains. Each confirmed case is logged with precise geographic coordinates and timestamps, allowing public health officials to trace the emergence and migration patterns of variants in real time. This data-driven approach has enabled the CDC to pinpoint the initial appearance of BA.3.2, a variant that by February 11, 2026, had been detected in at least 23 countries. Notably, four U.S. travelers tested positive through the Traveler Genomics Surveillance (TGS) program after returning from Japan, Kenya, the Netherlands, and the United Kingdom. These findings underscore the role of international travel in variant dissemination and highlight the importance of global genomic monitoring networks.

The latest seasonal vaccine, designed for the 2025–2026 immunization cycle, demonstrates strong efficacy against the JN.1 strains that dominate current outbreaks. However, laboratory tests comparing the vaccine's neutralizing capacity against seven variants revealed a significant gap in protection against BA.3.2. While this suggests reduced effectiveness in preventing infection by BA.3.2, experts emphasize that the vaccine still provides robust defense against severe disease outcomes. Current data indicates that even if BA.3.2 evades immune responses more effectively than other variants, hospitalization and fatality rates remain low among vaccinated individuals. Researchers stress that real-world clinical outcomes must be analyzed before drawing definitive conclusions about the variant's threat level.

Public health advisories from the CDC reinforce the importance of vigilance during illness. Most individuals infected with COVID-19 can recover at home by resting and using over-the-counter medications to manage symptoms. However, immediate medical attention is required if symptoms escalate to include difficulty breathing, persistent chest pain or pressure, new confusion, an inability to stay awake or wake up, or bluish discoloration of the lips or face. These signs signal potentially life-threatening complications that demand urgent intervention. For those at elevated risk—such as the elderly, individuals with chronic health conditions, or people with compromised immune systems—the CDC recommends contacting a healthcare provider promptly after testing positive. Antiviral treatments may be prescribed to mitigate disease severity and reduce hospitalization risks. These guidelines reflect a balance between public health preparedness and individual responsibility in managing infectious disease threats.